Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD Interaction of Tegoprazan and NOACs in Healthy Volunteers
NCT05723510Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Mar 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) (6 arms), sponsored by HK inno.N Corporation. Primary endpoints: Area Under the Concentration-Time Curve over a dosing interval, Maximum steady-state plasma concentration and 4 more. Started Mar 2023; status: completed.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05723510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723510.